NCT00836381View on ClinicalTrials.gov

Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

PHASE4CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Overactive Bladder

Interventions

DRUG

Tolterodine extended-release (ER) 4mg

Tolterodine extended-release (ER) 4mg once daily for 12 weeks

DRUG

Placebo

Identical Placebo once daily

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Samsung Medical Center

OTHER